Salmon in Pregnancy Study (NCT00801502) | Clinical Trial Compass
CompletedNot Applicable
Salmon in Pregnancy Study
United Kingdom124 participantsStarted 2007-05
Plain-language summary
The number of infants and children with allergic disease (dermatitis, allergies, asthma) has increased over the last several decades. This may be related to changes in diet. It is now thought that children become sensitised to allergens very early in life maybe even before they are born. Some studies show that a high omega-3 fat intake by mothers decreases risk of sensitisation in their babies. There is a biological mechanism to explain this. Omega-3 fats are found in oily fish like salmon. In the UK pregnant women are recommended to eat oily fish twice per week. However, consumption of oily fish is known to be low in pregnant women in the UK. This study sets out to identify the effects of increasing salmon intake in pregnant women. The hypothesis being investigated is that : increased consumption of oily fish during pregnancy by women at risk of having offspring who will develop atopy will increase their omega-3 fat and antioxidant status and that of their developing baby and will ameliorate the development of atopic markers and manifestations in the infants.
Who can participate
Age range18 Years – 40 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Pregnant women before 19 weeks gestation, with healthy uncomplicated singleton pregnancies, but whose babies are at risk of atopy (i.e. one or more first degree relatives affected).
✓. Not habitual consumers of oily fish (\< 2 portions of oily fish per month excluding tinned tuna).
✓. Not using fish oil supplements (currently or in the last 3 months)
✓. Age 18-40 y.
Exclusion criteria
✕. Habitual consumer of oily fish (\> 2 portions of oily fish per month excluding tinned tuna).
✕. Use of fish oil supplements within the previous 3 months.
✕. Not willing for essential identifiable information being stored for tracking purposes.
✕. Participation in another research study.
✕. Known diabetic and/or other auto-immune disease, e.g. SLE, MS, Thyroid Disease.
What they're measuring
1
Omega-3 fatty acid status in maternal and umbilical cord plasma
Timeframe: Weeks 20, 34 and 38 of pregnancy and at birth (in cord)
Trial details
NCT IDNCT00801502
SponsorUniversity Hospital Southampton NHS Foundation Trust